KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Payables (2019 - 2025)

Historic Payables for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $19.4 million.

  • Royalty Pharma's Payables rose 4513.09% to $19.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.4 million, marking a year-over-year increase of 4513.09%. This contributed to the annual value of $19.4 million for FY2025, which is 4513.09% up from last year.
  • As of Q4 2025, Royalty Pharma's Payables stood at $19.4 million, which was up 4513.09% from $41.4 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Payables peaked at $41.4 million during Q3 2025, and registered a low of $5.6 million during Q4 2021.
  • Its 5-year average for Payables is $15.3 million, with a median of $12.8 million in 2022.
  • In the last 5 years, Royalty Pharma's Payables plummeted by 7266.78% in 2021 and then soared by 30309.86% in 2024.
  • Over the past 5 years, Royalty Pharma's Payables (Quarter) stood at $5.6 million in 2021, then surged by 40.68% to $7.9 million in 2022, then skyrocketed by 91.82% to $15.2 million in 2023, then dropped by 11.84% to $13.4 million in 2024, then soared by 45.13% to $19.4 million in 2025.
  • Its Payables stands at $19.4 million for Q4 2025, versus $41.4 million for Q3 2025 and $20.2 million for Q2 2025.